Steven Everett 1

Steven Everett, MBA, Ph.D.

Chief Executive Officer

Steven Everett is a seasoned biotechnology executive and scientific leader with 25 years of experience in managing drug discovery and development programs as well as business development opportunities in world-renowned academic institutions and biotech companies, with deep experience in oncology, venture capital financing, and strategic partnership generation. His passion is in the exploitation of cutting-edge academic research, novel drug discovery paradigms, and translational science to progress groundbreaking drug treatment options to patients suffering from cancer. He has held numerous roles including CEO, CSO, entrepreneur-in-residence, strategic advisory, and business development in private and public biotech companies where he has successfully led Series A and B rounds of financing, and strategic partnership deals in Europe, China, and the US.

Steve has held professorships at world-class academic institutions in both the US and UK including the University of California San Francisco in Pharmaceutical Chemistry, the University of Dundee College of Life Sciences as Head of Drug Discovery and Translational Research, and the University of Oxford, CRUK/MRC Oxford Institute for Radiation Oncology (formerly the Gray Cancer Institute). Steve was awarded funding by Cancer Research UK for 14 years to project and program grant level through internationally peer-reviewed science. He was awarded the Steiner International Award for Cancer Research in 2003. 

Steve was awarded an MBA from the University of London and a double doctorate from the University of Ulster and the Hahn-Meitner-Institut Berlin in Radiation Chemistry and Biology. He is a Professional member of both the Royal Societies of Chemistry and Biology.  He is the lead and co-author of over 100 scientific publications and 50 issued patents and patent applications including licensed intellectual property and patent families now owned by MaveriX.